Drug Trial Radar · NCT07900945
Study of Single and Multiple Ascending Doses of CM551 in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-parallel controlled phase I study to evaluate the safety and tolerability of single and multiple doses of CM551 in healthy participants
Conditions
- Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
Interventions
CM551Biological
Participants will receive single subcutaneous doses of CM551 solution in a dose escalation format across 4 sequential SAD cohorts.
PlaceboDrug
Participants will receive single subcutaneous doses of CM551-matching placebo solution in a dose escalation format across 4 sequential SAD cohorts.
CM551Biological
Participants will receive repeated subcutaneous doses of CM551 solution in a dose escalation format across 2 sequential MAD cohorts.
PlaceboDrug
Participants will receive repeated subcutaneous doses of CM551-matching placebo solution in a dose escalation format across 2 sequential MAD cohorts.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: through study completion, an average of 1.5 years
- Incidence of Treatment-Emergent Adverse EventsTime frame: through study completion, an average of 1.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.